Sean Whooley

Brookline, Massachusetts

Assistant Editor, Life Sciences at MassDevice

Assistant Editor, Life Sciences at Drug Discovery & Development

Assistant Editor, Life Sciences at Medical Tubing + Extrusion

Assistant Editor, Life Sciences at WTWH Media LLC

Assistant Editor at @MassDevice/@WTWH_Media

Featured in: Favicon

massdevice.com Favicon

drugdiscoverytrends.com Favicon

usnews.com Favicon

miamiherald.com Favicon

washingtontimes.com Favicon

charlotteobserver.com Favicon

kansascity.com Favicon

wtop.com

star-telegram.com Favicon

newsobserver.com + 50 more

Articles

Lilly to submit once-weekly insulin for regulatory review this year

5 days ago | drugdeliverybusiness.com | Sean Whooley

Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively.
Study finds MannKind inhaled insulin safe, effective for children

5 days ago | drugdeliverybusiness.com | Sean Whooley

New study results demonstrated the safety and efficacy of the MannKind Afrezza inhaled insulin offering for children with type 1 diabetes. Investigators presented findings from the INHALE-1 study as a symposium at the American Diabetes Association’s 85th Scientific Sessions. The data showed that inhaled insulin offers a safe and effective replacement for rapid-acting meal insulin in children with type 1.
A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology

5 days ago | massdevice.com | Sean Whooley

Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely.
Glucotrack explains 3-year implant

5 days ago | drugdeliverybusiness.com | Sean Whooley

Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely.
Dexcom continues advances in AI for CGM, type 2 diabetes awareness

5 days ago | massdevice.com | Sean Whooley

As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and COO Jake Leach explained how the company continues to drive interest in its sensor platforms.
Dexcom continues advances in AI for CGM, type 2 awareness

5 days ago | drugdeliverybusiness.com | Sean Whooley

As one of the leaders in continuous glucose monitoring (CGM) technology, Dexcom (Nadsaq:DXCM) continues to expand its capabilities. The company has hit a number of milestones recently, including updated CGMs, new AI capabilities, expanded partnerships and more. Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, Dexcom President and COO Jake Leach explained how the company continues to drive interest in its sensor platforms.
Tandem continues to deliver more options, benefits for those with diabetes

5 days ago | massdevice.com | Sean Whooley

It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the flagship t:slim X2 and the Mobi miniature durable pump — that feature sophisticated software and connectivity to the market’s leading continuous glucose monitors (CGMs). And it continues to build on them.
Tandem delivers more options, benefits for those with diabetes

5 days ago | drugdeliverybusiness.com | Sean Whooley

It’s been a busy couple of years for Tandem Diabetes Care (Nasdaq:TNDM) and it doesn’t look like slowing down any time soon. The San Diego-based automated insulin delivery system developer offers two differentiated pump platforms — the flagship t:slim X2 and the Mobi miniature durable pump — that feature sophisticated software and connectivity to the market’s leading continuous glucose monitors (CGMs). And it continues to build on them.
Levita Magnetics surgical robot receives expanded FDA clearance

6 days ago | therobotreport.com | Sean Whooley

Levita Magnetics this week announced it received expanded FDA 510(k) clearance for its MARS (magnetic-assisted robotic surgery) system. The FDA granted 510(k) clearance for its Magnetic Surgical System (MSS), combined with MARS, in bariatric and hiatal hernia repair. Mountain View, California-based Levita said the expanded indication reinforces its ability to support surgeons treating patients with obesity-related conditions.
Breaking: Sequel to launch twiist automated insulin delivery system next month

6 days ago | massdevice.com | Sean Whooley

Sequel Med Tech announced at the American Diabetes Association’s 85th Scientific Sessions in Chicago that it plans to launch its twiist system in July. Dr. Joanna Mitri, the company’s chief medical officer, shared the update in a Product Theater session at ADA today. Mitri said the company plans to launch the automated insulin delivery system on July 7. The company had said as recently as March that it previously expected a second-quarter launch.